TY - T1的再利用benzbromarone表示“肺”nary arterial hypertension: can channelling the past deliver the therapy of the future? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00583-2019 VL - 53 IS - 6 SP - 1900583 AU - Theilmann, Anne L. AU - Ormiston, Mark L. Y1 - 2019/06/01 UR - //www.qdcxjkg.com/content/53/6/1900583.abstract N2 - One of the most well-established hallmarks of pulmonary arterial hypertension (PAH) is the unique cellular phenotype of the pulmonary arterial smooth muscle cells (PASMCs) from PAH patients. This phenotype, which is defined by hypercontractility, excessive proliferation, apoptosis resistance and aerobic glycolysis, is intimately linked with plasma membrane depolarisation and elevated concentrations of cytosolic calcium ([Ca2+]cyt) [1–3].A new study identifies increases in the calcium activated chloride channel, TMEM16A, in the pulmonary arteries of IPAH patients and proposes the repurposing of benzbromarone, a non-specific inhibitor of the channel, as a novel therapy for the disease http://bit.ly/2ITN4ul ER -